Pfizer touts blockbuster drug for fibromyalgia
Pfizer is touting a late stage study of its painkiller Lyrica for the treatment of fibromyalgia, a little-understood chronic pain condition that is thought to result from neurological changes in how patients perceive pain. Patients taking the drug reported a 50 percent decrease in pain compared to those taking placebo, as well as improvements in overall health status and outcomes. The study results were submitted to the FDA as part of a supplemental NDA for Lyrica for the treatment of fibromyalgia. Currently, there are no approved treatments for the disease. Lyrica recently entered the ranks of blockbuster therapies, earning $1.2 billion in 2006. An additional indication for fibromyalgia could significantly increase the drug's profits.
- see Pfizer's release for more
Related Articles:
Lyrica gains blockbuster status. Report
Forest Labs reports Phase III failure for fibromyalgia drug. Report
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

